JP2005511656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511656A5 JP2005511656A5 JP2003548823A JP2003548823A JP2005511656A5 JP 2005511656 A5 JP2005511656 A5 JP 2005511656A5 JP 2003548823 A JP2003548823 A JP 2003548823A JP 2003548823 A JP2003548823 A JP 2003548823A JP 2005511656 A5 JP2005511656 A5 JP 2005511656A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- group
- alkylene
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 60
- 125000000217 alkyl group Chemical group 0.000 claims 53
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 125000002947 alkylene group Chemical group 0.000 claims 31
- 125000003118 aryl group Chemical group 0.000 claims 24
- -1 indrone Chemical compound 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 8
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000004122 cyclic group Chemical group 0.000 claims 8
- 125000004076 pyridyl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 6
- 208000030814 Eating disease Diseases 0.000 claims 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 6
- 239000002830 appetite depressant Substances 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 235000014632 disordered eating Nutrition 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims 4
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 4
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims 4
- 239000012964 benzotriazole Substances 0.000 claims 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 239000000883 anti-obesity agent Substances 0.000 claims 3
- 229940125710 antiobesity agent Drugs 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 claims 1
- SXKBTDJJEQQEGE-UHFFFAOYSA-N 3-(3,5-dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonic acid [4-(thiazol-2-ylsulfamoyl)-phenyl]-amide Chemical compound CCC=1OC2=CC(S(=O)(=O)NC=3C=CC(=CC=3)S(=O)(=O)NC=3SC=CN=3)=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 SXKBTDJJEQQEGE-UHFFFAOYSA-N 0.000 claims 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 claims 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims 1
- QTQMRBZOBKYXCG-MHZLTWQESA-N GW 1929 Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCN(C)C=1N=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 QTQMRBZOBKYXCG-MHZLTWQESA-N 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- 239000003288 aldose reductase inhibitor Substances 0.000 claims 1
- 150000001602 bicycloalkyls Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229960001761 chlorpropamide Drugs 0.000 claims 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims 1
- 229960004580 glibenclamide Drugs 0.000 claims 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004474 heteroalkylene group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
- 0 CC(C1)(C=CC(*=C)=C1O)NC(N(C(CC1)CC=C1c1cc(C#N)ccc1)N(C)C)=O Chemical compound CC(C1)(C=CC(*=C)=C1O)NC(N(C(CC1)CC=C1c1cc(C#N)ccc1)N(C)C)=O 0.000 description 6
- LZAMLBFWTLFDKM-RXMQYKEDSA-N CC(C)N[C@@H](C)O Chemical compound CC(C)N[C@@H](C)O LZAMLBFWTLFDKM-RXMQYKEDSA-N 0.000 description 1
- WGLCVIHKXDMDGV-NVNXTCNLSA-N CCCCC1(CC/C=C(/CC=C2)\C=C2C#N)CC1 Chemical compound CCCCC1(CC/C=C(/CC=C2)\C=C2C#N)CC1 WGLCVIHKXDMDGV-NVNXTCNLSA-N 0.000 description 1
- FATOUWYXFUDWPE-UHFFFAOYSA-N CN1CN(CCCNC(Nc(cc2Cl)ccc2F)=O)CC1 Chemical compound CN1CN(CCCNC(Nc(cc2Cl)ccc2F)=O)CC1 FATOUWYXFUDWPE-UHFFFAOYSA-N 0.000 description 1
- QVYQPUPDVBARSC-MKWMUHEDSA-N N#CC(C1)CC=CC1C(C1)C(CC2)[C@H]1[C@@H]2N(CN(CC1)CC1O)C(Nc(cc1C(CCF)F)ccc1F)=O Chemical compound N#CC(C1)CC=CC1C(C1)C(CC2)[C@H]1[C@@H]2N(CN(CC1)CC1O)C(Nc(cc1C(CCF)F)ccc1F)=O QVYQPUPDVBARSC-MKWMUHEDSA-N 0.000 description 1
- VBOMXJWPUDJWDX-UHFFFAOYSA-N N=C(CCC1)CC1C(CC1)CCC1N(CCN1CCCC1)C(NC(CCC1F)CC1C(F)(F)F)O Chemical compound N=C(CCC1)CC1C(CC1)CCC1N(CCN1CCCC1)C(NC(CCC1F)CC1C(F)(F)F)O VBOMXJWPUDJWDX-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33726201P | 2001-12-04 | 2001-12-04 | |
| US39985302P | 2002-07-31 | 2002-07-31 | |
| PCT/US2002/038408 WO2003047568A1 (en) | 2001-12-04 | 2002-12-03 | N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009118103A Division JP2009235076A (ja) | 2001-12-04 | 2009-05-14 | 肥満の処置のためのｍｃｈアンタゴニストとしてのｎ−アリール−ｎ’−アリールシクロアルキル−尿素−誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005511656A JP2005511656A (ja) | 2005-04-28 |
| JP2005511656A5 true JP2005511656A5 (enExample) | 2006-03-09 |
| JP4330996B2 JP4330996B2 (ja) | 2009-09-16 |
Family
ID=26990617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003548823A Expired - Fee Related JP4330996B2 (ja) | 2001-12-04 | 2002-12-03 | 肥満の処置のためのｍｃｈアンタゴニストとしてのｎ−アリール−ｎ’−アリールシクロアルキル−尿素−誘導体 |
| JP2009118103A Pending JP2009235076A (ja) | 2001-12-04 | 2009-05-14 | 肥満の処置のためのｍｃｈアンタゴニストとしてのｎ−アリール−ｎ’−アリールシクロアルキル−尿素−誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009118103A Pending JP2009235076A (ja) | 2001-12-04 | 2009-05-14 | 肥満の処置のためのｍｃｈアンタゴニストとしてのｎ−アリール−ｎ’−アリールシクロアルキル−尿素−誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7348328B2 (enExample) |
| EP (1) | EP1453501B1 (enExample) |
| JP (2) | JP4330996B2 (enExample) |
| KR (1) | KR20050044664A (enExample) |
| CN (1) | CN1617718A (enExample) |
| AR (1) | AR037621A1 (enExample) |
| AT (1) | ATE404190T1 (enExample) |
| AU (1) | AU2002348269A1 (enExample) |
| CA (1) | CA2468967A1 (enExample) |
| DE (1) | DE60228317D1 (enExample) |
| ES (1) | ES2312637T3 (enExample) |
| HU (1) | HUP0500034A2 (enExample) |
| IL (1) | IL162311A0 (enExample) |
| MX (1) | MXPA04005503A (enExample) |
| PE (1) | PE20030680A1 (enExample) |
| TW (1) | TW200302719A (enExample) |
| WO (1) | WO2003047568A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2006110272A (ru) | 2003-10-01 | 2007-11-10 | Дзе Проктер Энд Гэмбл Компани (US) | Антагонисты гормона, концентрирующего меланин |
| JP2007507533A (ja) * | 2003-10-02 | 2007-03-29 | シェーリング コーポレイション | 肥満および関連障害の処置のための、選択的メラニン凝集ホルモンレセプターアンタゴニストとしてのアミノベンズイミダゾール |
| DE102004003811A1 (de) * | 2004-01-25 | 2005-08-11 | Aventis Pharma Deutschland Gmbh | Substituierte N-Cyclohexylimidazolinone, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| CN101014589A (zh) * | 2004-07-16 | 2007-08-08 | 先灵公司 | 作为选择性黑色素聚集激素拮抗剂的新型杂环和其用于治疗肥胖症及相关疾病 |
| US20070043100A1 (en) | 2005-08-16 | 2007-02-22 | Hagen Eric J | Novel polymorphs of azabicyclohexane |
| EP1807409A2 (en) * | 2004-10-12 | 2007-07-18 | Pharmacopeia Drug Discovery, Inc. | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
| AU2005305036B2 (en) * | 2004-11-01 | 2011-03-10 | Amylin Pharmaceuticals, Llc | Treatment of obesity and related disorders |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| ES2325773T5 (es) * | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals, Llc. | Tratamiento de la obesidad y de los trastornos relacionados |
| JPWO2006104280A1 (ja) * | 2005-03-31 | 2008-09-11 | 武田薬品工業株式会社 | 糖尿病の予防・治療剤 |
| US7799943B2 (en) * | 2005-06-24 | 2010-09-21 | Rohm And Haas Company | Method for promoting Michael addition reactions |
| AU2006275870B2 (en) | 2005-07-27 | 2013-01-10 | Otsuka America Pharmaceutical, Inc. | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders |
| US20080045725A1 (en) | 2006-04-28 | 2008-02-21 | Murry Jerry A | Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane |
| US8138377B2 (en) * | 2006-11-07 | 2012-03-20 | Dov Pharmaceutical, Inc. | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
| US20080269348A1 (en) * | 2006-11-07 | 2008-10-30 | Phil Skolnick | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use |
| JP2010528007A (ja) * | 2007-05-23 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | シクロプロピルピロリジンオレキシン受容体アンタゴニスト |
| US9133159B2 (en) | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| EP2036578A1 (en) * | 2007-09-13 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | Diagnostic agents for positron emission imaging using F-18 radio labeled amino-alcohols |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| CN102875385A (zh) * | 2012-10-18 | 2013-01-16 | 浙江大学 | N,n-二异丙基乙胺的合成方法 |
| JP2019527693A (ja) | 2016-08-03 | 2019-10-03 | サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物 |
| MX2021015573A (es) * | 2019-06-28 | 2022-04-06 | Rti Int | Derivados de urea como moduladores alostericos de cb1. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW209868B (enExample) * | 1991-04-04 | 1993-07-21 | Yoshitomi Pharmaceutical | |
| US5908830A (en) * | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| AU5135998A (en) | 1996-12-03 | 1998-06-29 | Banyu Pharmaceutical Co., Ltd. | Novel urea derivatives |
| IL139913A0 (en) | 1998-06-08 | 2002-02-10 | Schering Corp | Neuropeptide y5 receptor antagonists |
| GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
-
2002
- 2002-12-03 AU AU2002348269A patent/AU2002348269A1/en not_active Abandoned
- 2002-12-03 CN CNA028277554A patent/CN1617718A/zh active Pending
- 2002-12-03 ES ES02782401T patent/ES2312637T3/es not_active Expired - Lifetime
- 2002-12-03 DE DE60228317T patent/DE60228317D1/de not_active Expired - Lifetime
- 2002-12-03 WO PCT/US2002/038408 patent/WO2003047568A1/en not_active Ceased
- 2002-12-03 HU HU0500034A patent/HUP0500034A2/hu unknown
- 2002-12-03 IL IL16231102A patent/IL162311A0/xx unknown
- 2002-12-03 JP JP2003548823A patent/JP4330996B2/ja not_active Expired - Fee Related
- 2002-12-03 AT AT02782401T patent/ATE404190T1/de not_active IP Right Cessation
- 2002-12-03 TW TW091135038A patent/TW200302719A/zh unknown
- 2002-12-03 AR ARP020104668A patent/AR037621A1/es unknown
- 2002-12-03 CA CA002468967A patent/CA2468967A1/en not_active Abandoned
- 2002-12-03 EP EP02782401A patent/EP1453501B1/en not_active Expired - Lifetime
- 2002-12-03 KR KR1020047008490A patent/KR20050044664A/ko not_active Withdrawn
- 2002-12-03 US US10/308,782 patent/US7348328B2/en not_active Expired - Fee Related
- 2002-12-03 MX MXPA04005503A patent/MXPA04005503A/es not_active Application Discontinuation
- 2002-12-03 PE PE2002001165A patent/PE20030680A1/es not_active Application Discontinuation
-
2009
- 2009-05-14 JP JP2009118103A patent/JP2009235076A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005511656A5 (enExample) | ||
| JP2005510563A5 (enExample) | ||
| JP2005507918A5 (enExample) | ||
| CA2464130A1 (en) | Mch antagonists for the treatment of obesity | |
| CA2467857A1 (en) | Piperidine-based mch antagonists for treatment of obesity and cns disorders | |
| US6562807B2 (en) | Glucagon antagonists/inverse agonists | |
| JP2010538076A5 (enExample) | ||
| HRP20141048T1 (hr) | Spojevi, pripravci i metode | |
| CA2441239A1 (en) | Mch antagonists and their use in the treatment of obesity | |
| JP2011527334A5 (enExample) | ||
| MY136034A (en) | New medicaments for the treatment of chronic obstructive pulmonary disease | |
| JP2005509024A5 (enExample) | ||
| CN1466569A (zh) | 新型3-取代的脲衍生物及其药学应用 | |
| EP1509509A1 (en) | Glucagon antagonists/inverse agonists | |
| JP2002501049A5 (enExample) | ||
| TW200407327A (en) | Calcitonin gene related peptide receptor antagonists | |
| JP2005539088A5 (enExample) | ||
| JP2008513504A5 (enExample) | ||
| RU2005139525A (ru) | N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы | |
| JP2004517087A5 (enExample) | ||
| JP2005535641A5 (enExample) | ||
| CN1274288A (zh) | 含肽的α－酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂 | |
| JP2006510673A5 (enExample) | ||
| US7141590B2 (en) | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | |
| JP2007502817A5 (enExample) |